Abstract
Autism spectrum disorder (ASD) and Fragile X syndrome (FXS) are relatively common childhood neurodevelopmental disorders with increasing incidence in recent years. They are currently accepted as disorders of the synapse with alterations in different forms of synaptic communication and neuronal network connectivity. The major excitatory neurotransmitter system in brain, the glutamatergic system, is implicated in learning and memory, synaptic plasticity, neuronal development. While much attention is attributed to the role of metabotropic glutamate receptors in ASD and FXS, studies indicate that the ionotropic glutamate receptors (iGluRs) and their regulatory proteins are also altered in several brain regions. Role of iGluRs in the neurobiology of ASD and FXS is supported by a weight of evidence that ranges from human genetics to in vitro cultured neurons. In this review we will discuss clinical, molecular, cellular and functional changes in NMDA, AMPA and kainate receptors and the synaptic proteins that regulate them in the context of ASD and FXS. We will also discuss the significance for the development of translational biomarkers and treatments for the core symptoms of ASD and FXS.
Keywords: AMPA receptor, Arc, autism spectrum disorder, Fragile X syndrome, GRIP1/2, kainate receptor, MAP1B, memantine, metabotropic glutamate receptor, neuroligin, NMDA receptor.
Current Neuropharmacology
Title:The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome
Volume: 12 Issue: 1
Author(s): Genoveva Uzunova, Eric Hollander and Jason Shepherd
Affiliation:
Keywords: AMPA receptor, Arc, autism spectrum disorder, Fragile X syndrome, GRIP1/2, kainate receptor, MAP1B, memantine, metabotropic glutamate receptor, neuroligin, NMDA receptor.
Abstract: Autism spectrum disorder (ASD) and Fragile X syndrome (FXS) are relatively common childhood neurodevelopmental disorders with increasing incidence in recent years. They are currently accepted as disorders of the synapse with alterations in different forms of synaptic communication and neuronal network connectivity. The major excitatory neurotransmitter system in brain, the glutamatergic system, is implicated in learning and memory, synaptic plasticity, neuronal development. While much attention is attributed to the role of metabotropic glutamate receptors in ASD and FXS, studies indicate that the ionotropic glutamate receptors (iGluRs) and their regulatory proteins are also altered in several brain regions. Role of iGluRs in the neurobiology of ASD and FXS is supported by a weight of evidence that ranges from human genetics to in vitro cultured neurons. In this review we will discuss clinical, molecular, cellular and functional changes in NMDA, AMPA and kainate receptors and the synaptic proteins that regulate them in the context of ASD and FXS. We will also discuss the significance for the development of translational biomarkers and treatments for the core symptoms of ASD and FXS.
Export Options
About this article
Cite this article as:
Uzunova Genoveva, Hollander Eric and Shepherd Jason, The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome, Current Neuropharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/1570159X113116660046
DOI https://dx.doi.org/10.2174/1570159X113116660046 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Postnatal Repeated Mild Stress and DEγE Treatment Induce a Reduction of S of DBA/2J in Mice
Letters in Drug Design & Discovery Preserving Brain Function During Development and Aging with Erythropoietin
Current Neurovascular Research Progress and Outlooks in a Genetic Absence Epilepsy Model (WAG/Rij)
Current Medicinal Chemistry Mossy Fiber Sprouting as a Potential Therapeutic Target for Epilepsy
Current Neurovascular Research Non-Antidepressant Treatment of Generalized Anxiety Disorder
Current Clinical Pharmacology Approaches to Mitochondrial Gene Therapy
Current Gene Therapy Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry The Potential of Caffeine for Functional Modification from Cortical Synapses to Neuron Networks in the Brain
Current Neuropharmacology Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases
Current Drug Targets The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction
Current Pharmaceutical Design Neural Correlates in Patients with Major Affective Disorders: An fMRI Study
CNS & Neurological Disorders - Drug Targets Recent Developments in Oxidative Processes in Steroid Chemistry
Current Organic Chemistry Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry Combating Mosquito-Borne Lymphatic Filariasis with Genomics Technologies: Enabling Novel Drug Discovery for Neglected Tropical Diseases
Current Pharmacogenomics and Personalized Medicine Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies
Current Neuropharmacology P-Glycoprotein Contributes to Cell Membrane Depolarization of Hippocampus and Neocortex in a Model of Repetitive Seizures Induced by Pentylenetetrazole in Rats
Current Pharmaceutical Design Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry Herbal Medicine in the Treatment of Epilepsy
Current Drug Targets The Long Run: Neuroprotective Effects of Physical Exercise on Adult Neurogenesis from Youth to Old Age
Current Neuropharmacology